Good afternoon, everyone, and welcome to the Atea Pharmaceuticals' Third Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in the listen-only mode. Following the formal remarks, we will open the call up for your questions. I would now like to turn the call over to Jonae Barnes, Senior Vice President of Investor Relations and Corporate Communications at Atea Pharmaceuticals. Ms. Barnes, please proceed. Thank you, Operator. Good afternoon, everyone, and welcome to Atea Pharmaceuticals' Third Quarter 2024 Financial Results and Business Update Conference Call. Earlier today, we issued a press release which outlines the topics we plan to discuss. You can access the press release as well as the slides that we'll be reviewing today by going to the investor section of our website at ir.ateapharma.com. With me today from Atea are our Chief Executive Officer and Founder, Dr. Jean-Pierre Sommadossi, Chief Development Officer, Dr. Janet Hammond, John Vavricka, our Chief Commercial Officer, Dr. Arantxa Horga, our Chief Medical Officer, and Chief Financial Officer and Executive Vice President of Legal, Andrea Corcoran. They will all be available for the Q&A portion of today's call. Before we begin the call, and as outlined on slide two, I would like to remind you that today's discussion will contain forward-looking statements that involve risk and uncertainties. These risks and uncertainties are outlined in today's press release and in the company's recent filings with the Securities and Exchange Commission, which we encourage you to read. Our actual results may differ materially from what is discussed on today's call. With that, I'll now turn the call over to Jean-Pierre. Thank you, Jonae. Good afternoon, everyone, and thank you for joining us. I will begin on slide three. It has been a busy year so far, and our team has executed on two large global clinical programs on time and on budget. Unfortunately, as we reported in September, we did not have the desired outcome for SUNRISE-3 as we had hoped for. COVID-19 variants are constantly evolving, as you know, and the natural history trended toward milder disease, which has resulted in fewer hospitalizations and deaths. Of particular importance, in contrast to our prior studies, hospitalization due to severe respiratory disease, including pneumonia, was not observed in SUNRISE-3. Therefore, it is quite difficult for a direct-acting antiviral to demonstrate a significant impact on the course of the disease. I am proud of our team's rigorous execution of this trial, and we thank the study participants and the investigators. Our efforts are now concentrated on our global HCV program, and we remain on track to report top-line results for our phase II study in early December. We then anticipate holding an end-of-phase II meeting with the FDA early next year and initiating the phase III program shortly thereafter. For someone who has worked in HCV for most of my career, the unrelenting high rate of HCV infections in the U.S. underscored the need for new innovative therapies for today's patients, particularly for those with substance abuse disorder and comorbidities. Injection drug use accounts for about 30% of new HCV cases globally, and approximately actually 60% in the U.S., where between two and four million people are estimated to be infected with HCV. Annually, HCV diagnoses in the U.S. outpace treatment rates, as less than a third of those diagnosed with HCV receive timely treatment. We believe that our combination, with its potential best-in-class profile as the ability to address current treatment challenges and unmet needs, and to play a major role in the eradication of HCV in the U.S. We also continue to make progress with our early-stage discovery program, evaluating a highly differentiated second-generation protease inhibitors, which is targeting RNA respiratory viruses. Importantly, with $482.8 million of cash, cash equivalent, and marketable securities as of September 30, we are in a strong financial position to execute and complete our HCV program phase III. Our HCV phase III program, and we anticipate our runway to extend well into 2027. With that, I will now turn the call over to Janet to review our phase III readiness for the HCV program and the profile to today's HCV patients. Janet? Thanks, Jean-Pierre. Turning to slide four, we believe that our global phase III ready HCV program is de-risked with a compelling value proposition. This is based on the substantial preclinical and clinical data already generated on bemnifosbuvir and ruzasvir, both alone and in combination, coupled with a well-characterized regulatory pathway. Furthermore, our program has a potential best-in-class profile, and all that with a long IP runway. Let's review the activities underway to initiate our global phase III program. For manufacturing, our six-dose tablet is ready for the phase III global program. Our API and manufacturing processes have been optimized, and we are already prepared for commercial-scale production. There is a clear regulatory pathway with HCV. We are planning an end-of-phase II meeting with the FDA early next year to finalize our phase III program and expect to conduct two global phase III studies with an active comparison starting early next year. Leveraging the work and relationships already existing from our phase II study, we have global clinical trial sites that are prepared and excited to participate in our phase III program. Additionally, our contract research organization and central labs are already engaged in startup activities ahead of the phase III initiation. Finally, our intellectual property provides broad global coverage and a long patent protection until at least 2042. The branded treatments Epclusa, including its authorized copy and Mavyret, also have long patent runways with IP protection to 2036, which should allow for stable pricing in the foreseeable future for the HCV market. On slide six, the profile of today's HCV infected patients has shifted since the introduction of direct-acting antivirals. Now, the majority of U.S. infected patients are younger, and HCV infections predominate in patients in the age group between 20 to 49 years, with less than 10% of HCV patients being cirrhotic. This is because the progression to cirrhosis from HCV infection normally takes about 20 years, and since patients have been trending younger, they have not been infected for an extended length of time yet. The patients who are at the highest risk for HCV in 2024 are frequently poorly adherent to their medications due to substance abuse disorders, including opioid use or other drugs, and many have mental health disorders. In addition, a high proportion of the current patients take multiple concomitant medications, including HIV medications, hormonal contraceptives, statins, and proton pump inhibitors. For this patient profile, a direct-acting antiviral combination with a low risk of drug interactions, no food effect, combined with a short treatment duration, is clearly beneficial. We believe that the target profile of our combination has the potential to address these unmet needs. It may also treat more patients successfully and could expand the number of patients cured. I'll now hand the call over to John to review the antiviral market opportunity for HCV. John? Thank you, Janet. Turning to slide seven, today's patient profile presents new challenges and requires an improved drug profile. Rigorous market research suggests that a very large number, approximately 94%, of the Epclusa and Mavyret prescribers are not satisfied with current treatment options. First, treatment adherence is a challenge. Patients who use drugs are often unable to get into medical care and maintain treatment adherence due to chaotic life circumstances. In fact, healthcare professionals have reported that 17% of patients fail to complete a full course of therapy. An ideal HCV therapy should provide high efficacy with a short length of therapy. Secondly, a longitudinal analysis of HCV patients showed 80% of patients who initiated direct-acting antiviral therapy are often on medications for other medical conditions, and an ideal HCV therapy should allow patients to take concomitant medications without drug interaction risk. Finally, taking these medications with food may be an issue. In particular, patients who use drugs consider food requirements with therapy challenging, and ideal HCV therapy should not be dependent on taking with or without food. Neither Epclusa nor Mavyret can address all these challenges. Mavyret has a short duration of therapy, but is hampered by its drug-drug interaction profile, and it needs to be administered with food. Epclusa has a long duration of therapy, which limits its convenience. Slide eight outlines the current HCV market in the United States. HCV continues to be a recognized healthcare crisis in the U.S., with between two and four million living with HCV, and new challenges continue to hinder the progress towards eliminating it globally. The U.S. HCV commercial market is expected to remain large, with net sales of approximately $1.5 billion. The market demand grew roughly 5% in 2023 versus 2022, based on the number of patients treated, with the market shares of the two key HCV treatment options, Epclusa and Mavyret, remaining stable, and for the first half of 2024, we have seen a slight increase in pricing with stable market share. Also interesting to note is the U.S. patient pool continues to be replenished with approximately 100,000 new chronic cases each year. We believe future U.S. government initiatives and the removal of certain constraints by payers and other access barriers, combined with the best-in-class profile, have the potential to expand the number of patients cured from this severe viral disease. With that, I will now turn the call over to Arantxa for a review of our global phase II HCV study. Thank you, John. On slide 10, we would like to remind you of the outline of our phase II single-arm, open-label study of 550 milligrams of bemnifosbuvir in combination with 180 milligrams of ruzasvir once daily for eight weeks. This phase II trial, which is nearing completion, enrolled 275 treatment naive patients, including the lead-in cohort of 16 non-cirrhotic patients. We are looking forward to reporting the top-line results in early December. Slide 11 reviews how we will be reporting the efficacy analysis of the study populations for the phase II trial. The primary efficacy analysis of the study is sustained virological response at 12 weeks post-treatment, or SVR12, in the per-protocol treatment adherent population, as measured by pill count and confirmed by adequate drug exposures. A secondary efficacy analysis will assess SVR12 in the per-protocol population, regardless of treatment adherence. This is also referred to as the efficacy evaluable population and includes patients in the analysis whether or not they were treatment adherent. We will report data in both populations. Turning to slide 12, at EASL, we presented data from the lead-in cohort of 60 patients. We are very pleased with these results, which show a high SVR12 rate of 97% with a short eight-week duration of treatment. Importantly, the only two patients with post-treatment relapse or failure illustrate the challenge of drug adherence in this patient population. The viral relapse or failure was due to treatment adherence, as demonstrated by inadequate drug levels, and not due to viral resistance, as confirmed by the lack of new viral mutations. Moving to slide 13, this slide shows the on-treatment viral kinetics of individual patient data from the lead-in cohort. As you can see, there was a rapid reduction of viral load in all patients within the first week, regardless of baseline viremia and genotype. By week four on treatment, all 60 patients in the leading cohort had a viral load near or below the lower limit of quantification. Therefore, these rapid kinetics across all genotypes support the eight-week regimen. Slide 14. In summary, all 60 patients in the leading cohort completed the eight-week treatment period. The combination treatment of bemnifosbuvir and ruzasvir was generally safe and well tolerated, with no drug-related severe adverse events or premature treatment discontinuation. Similarly, there were no trends observed in adverse events or safety laboratory parameters. I would also like to mention that next week, there are three poster presentations at AASLD, The Liver Meeting 2024, which include additional safety and resistance data for bemnifosbuvir and modeling data on the leading cohort from the phase II study. In addition, an integrated population pharmacokinetic model was developed to simultaneously characterize the pharmacokinetic profile of bemnifosbuvir and its metabolites. This data will be presented at the American College of Pharmacometrics Conference on November 11. I will now turn the call over to Andrea to discuss Atea financials. Thank you, Arantxa. As Jonae mentioned, earlier today, we issued a press release containing our financial results for the third quarter of 2024. The statement of operations and balance sheet are on slides 16 and 17. In the third quarter of 2024, R&D expenses decreased compared to the prior year period. This net decrease in 2024 is primarily driven by lower 2024 COVID-19 spending, offset by higher 2024 spending related to our HCV phase II clinical trial. For G&A expenses, there was a decrease in the current quarter compared to the corresponding period in 2023. This decrease was primarily the result of incurring lower professional fees in the third quarter of 2024. Interest income for the 2024 quarter decreased compared to the prior year period due to lower investment balances. For the remainder of 2024, we expect R&D spend will be principally related to the completion of the HCV phase II study and startup activities associated with our anticipated global HCV phase III program. At the end of the third quarter of 2024, our cash, cash equivalent, and marketable securities balance was $482.8 million. Continuing our strong financial discipline, we project our cash guidance runway well into 2027. I'll now hand the call back to Jean-Pierre for closing remarks. Thank you, Andrea. We are eagerly awaiting the top-line result from our phase II HCV study, which, as we have mentioned, is expected in early December, so just about a month from now. The combination of bemnifosbuvir and ruzasvir represent a potential best-in-class profile that combines the most compelling attributes of current HCV drug treatments, such as convenience, short duration, and low risk for drug-drug interaction. We believe that our combination is highly differentiated and has the opportunity to address significant unmet medical needs of today's HCV patients. We are looking forward to initiating our phase III development program early next year. Before opening the call to your questions, I would like to thank our talented and dedicated Atea employees. Our team is relentless, full of excellent drives, our dedication to advancing all antiviral therapeutics for patients worldwide affected by viral diseases. With that, I would turn the call back over to the operator. Thank you. We will now begin the question and answer session. If you have dialed in and would like to ask a question, please press star one on your telephone keypad to raise your hand and join the queue. If you'd like to withdraw your question, simply press star one again. If you are called upon to ask your question and are listening via loudspeaker on your device, please pick up your handset and ensure that your phone is not on mute when asking your question. Again, press star one to join the queue. And your first question comes from the line of Eric Joseph. Please go ahead. Hi, this is Bella Un for Eric. Thank you for taking our questions. First, how are you thinking about the phase III HCV trial design, particularly in the context of any remaining adherence obstacles and the use of an active comparator? And additionally, what parameters are you seeking clarity on going into your meeting with the FDA? Arantxa, you want to address those two questions? Yes, thank you for the question, so to answer the first one, we are planning to do randomized trials, and that will, in our opinion, address the issue of adherence because then you'll have a control arm, and then you can assess the population against the control. In terms of the meeting with the FDA, we are really proposing a development plan, a phase III development plan that is very much aligned with the FDA guidelines, and we're going to be submitting the data and then submitting these designs, which are aligned with what they are requiring, so I'm not sure what the FDA will say, but I think that we are pretty confident that our plan will be generally at least acceptable. Great. That's all for us. Thank you. Your next question comes from the line of Umer Raffat. Please go ahead. Oh, hi. This is Cheng Xiang for Umer. Thanks for taking our question. I guess first one, you've mentioned the drug exposure of fixed dose combination is comparable to individually administered drug, but have you seen any change in the PK profile for each drug component, especially in its half-life? No, absolutely not. I think we have shown the profile last time, and we are very pleased with the PK profile on both drugs, and we don't see any difference, both on drug exposure and individual parameters such as half-lives of both drugs. Okay, thank you. I also want to touch upon the phase III design. Is it going to be the same dose, like 550 milligram BEM and 180 milligram ruzasvir? And I've seen there's only one site in phase II, U.S. sites. Will it be the same like most of the sites for phase III, also ex-U.S.? Arantxa? So we're going to have U.S. sites a lot more than one. We only have one in phase II because that was what we got time to open in phase II. But no, in phase III, we're going to have a lot of U.S. sites and also a lot of sites ex-U.S. In terms of the dose, yes, it's going to be the same dose, but the beauty of it is that now we're going to have a fixed dose combination, and we think that that obviously decreases the pill burden, and that's going to help us also with adherence. We can mention Arantxa. I think we have more than 100 sites just in the U.S., right? Arantxa, what do you anticipate? Yeah, we're still identifying some of them, but what I can tell you is that we have a lot of interest from the sites. We're getting very, very strong response from investigators and sites in the United States, and also ex-U.S., but especially in the United States. All right. Thank you so much. Your next question comes from the line of Andy Hsieh. Please go ahead. Oh, great. Thanks for taking our questions. Maybe one on the phase III kind of aspiration, just given the active control. I'm curious if you're shooting for perhaps superiority or non-inferiority with a numerical benefit from the SVR12 perspective. Just try to gauge your temperature on that front. Do you want to address that, Arantxa? Yes. So the trial will be powered for non-inferiority, and we always allow a second test for superiority within the primary endpoint. So we are powering for non-inferiority, and we may even make a superiority. Andy has, yeah, go ahead. I'm sorry. Oh, go ahead. I'm sorry. I have a second question. Andy, please go ahead. As you know, for any drugs that are higher than 90% efficacy, we anticipate that the rule is that we anticipate a 5% non-inferiority. And so, based on the number of patients that we need for basically a safety database, we think that we have power of more than 90% with a size of about 800 patients. So we'll see what the FDA feedback as the end of phase II meetings, but we feel reasonably confident that we should be aligned. Excellent. Thanks for that. And maybe a commercial question, just on kind of volume-based contracts that we've seen previously, potentially be a low-hanging fruit, right? Just basically provide drugs, and the other entity would have to identify patients, making this pathway very cost-efficient. I'm just wondering how you think about that segment of the market and how much you'll utilize these types of frameworks? John? Yeah, thank you for the question. What I can comment on, at least, is what historically has gone on, and there are many pathways for utilization, particularly the traditional pathways, as well as with government entities, whether it be Medicare or Medicaid. And right now, the government continues to be one of the single larger payers in that regard. So the individual states would likely fall under the Medicaid situation. And it's been pretty relatively stable, and we don't see that changing in the foreseeable future. Could you comment on having sales reps in that kind of framework? Would it be less compared to the traditional framework, or it'll be comparable? What I can tell you is that if you look at the market overall, in this particular market with the magnitude of these sales, these are $1.5 billion of net sales in the United States. It's a very concentrated set of writers in the United States who prescribe these assets, and it's very efficient to go after them. Thank you so much. Thank you. That concludes our Q&A session. I will now turn the conference back over to Jean-Pierre for closing remarks. Thank you all for joining our third quarter 2024 earnings conference call, and thank you for your continued support. Ladies and gentlemen, that concludes today's call. Thank you all for joining. You may now disconnect.